Healthcare >> Analyst Interviews >> March 27, 2019
Scrutiny of Pharmacy Benefit Managers Resulting in Visibility of Drug Prices
Steve Brozak is the Managing Partner and President of WBB Securities, LLC. In 2013, Dr. Brozak was selected as a top analyst in the pharmaceuticals sector by the StarMine/Financial Times Industry Analyst Awards. He also was named to The Wall Street Journal’s “Best on the Street” list in the category of medical equipment and supplies. Earlier, Dr. Brozak worked in finance at Alex. Brown & Sons, Cowen & Company, Dean Witter and Salomon Brothers. Dr. Brozak has written for Nature, The British Medical Journal and Brain Stimulation. He is also a contributor to Forbes and ABC News. He received a B.A. degree and an MBA from Columbia University and a Doctorate in Medical Humanities — DMH — from Drew University. He served in the United States Marine Corps, retiring as a lieutenant colonel. Profile
Word count: 3,842
TWST: What is your general outlook on the biotech and pharma space for the rest of 2019?
Dr. Brozak: We are facing the most fluid health care,